Chief Executive Officer since January 2019 and Chief Medical Officer since December 2018. Born in 1976. Dr Agervald holds an MD and PhD from Uppsala University and is a board-certified specialist in internal medicine and nephrology. Dr Agervald is an associate professor and internationally recognized researcher within experimental and clinical nephrology and endocrinology. He performed parts of his PhD studies at Harvard Medical School and a postdoctoral fellowship at Indiana University School of Medicine. Dr Agervald has extensive global drug development experience in both early and later clinical stages, most recently from his position as Senior Medical Director at Astellas Pharma Global Clinical Development.
Previous positions: Senior Medical Director at Astellas Pharma. Global key opinion leader in cardio-renal disease and frequently engaged expert for analysis of pharmaceutical development projects and design and execution of clinical studies via advisory boards and steering committees.
Other appointments: Tobias Agervald is an adjunct associate professor at the Karolinska Institutet and has been an expert consultant, lecturer or advisory board member for large pharmaceutical companies such as AbbVie, Sanofi Aventis, Genzyme, Shire, Amgen, SOBI and Astellas.
Previous assignments in the last five years: Senior Medical Director, Astellas Pharma.
Shareholding: 1,042,693 shares.
CFO since September 14, 2020. Born 1973. Karin Botha holds a Degree of Master of Science in Business Administration and Economics and has more than 20 years of working experience from leading roles within finance in global pharmaceutical companies. Most recently as Controls and Compliance Specialist at Novartis.
Previous experience also includes positions such as Nordic Head of Financial Reporting and Accounting, Nordic Head of Business Planning and Analysis and Interim CFO.
Other engagements: board member of Matting AB
Previous assignments in the last five years: Specialist and Nordic Head of Financial Controls and Compliance at Novartis and Sandoz
Shareholding: 0 shares
CMC Head since March 2020. Born in 1967. Lars Olsson and is responsible for the CMC-activities in the company. He holds a Ph.D. in organic chemistry and have more than 20 years of pharmaceutical development experience with projects in both early and late phase.
Previous positions. Have been CMC responsible at Wilson Therapeutics and Karo Bio and managed various CMC projects and tasks at Acadia, Medivir and AstraZeneca. Previous experiences includes development of manufacturing processes, project management of external partners, participation in clinical study teams and company management.
Other appointments: Consultancy in the CMC field.
Previous assignments in the last five years: Wilson Therapeutics, Corline Biomedical, RG Pharma Development
Head of Preclinical Science
Head of Preclinical Science. Born in 1970. An expert in nonclinical drug discovery and developmental pharmacology, molecular biology and toxicology, Peter is responsible for all nonclinical science in Guard. He has a PhD in toxicology and more than 25 years’ experience in pharmaceutical discovery and clinical development, and drug repurposing in a variety of therapeutic areas.
His previous pharmaceutical career came from AstraZeneca and Astellas Pharma as pharmacologist in projects from discovery to regulatory filing.
Other Appointments: Consultancy in nonclinical drug development
Previous appointments in the last five years: Founder of The Drug Development Team, Astellas Pharma Europe and AstraZeneca, UK.